Hormonal Therapies Underused for GSM in Menopause
Hormonal therapies for genitourinary syndrome of menopause (GSM) are underutilized, with significant disparities in access. Research indicates that socioeconomic factors play a role in the likelihood of receiving treatment. The removal of a boxed warning by the FDA last year may help address some barriers to prescribing these therapies.
- ▪Only 55.4% of eligible patients with GSM received hormonal therapy after diagnosis.
- ▪Patients receiving therapy were more likely to be White, have higher education, and earn over $100,000 annually.
- ▪Untreated patients faced higher odds of delaying care due to transportation and rural location issues.
Opening excerpt (first ~120 words) tap to expand
Hormonal therapies are indicated for genitourinary syndrome of menopause (GSM), but the therapies are underused and access is inequitable, new data presented as a poster at the American Urological Association (AUA) 2026 Annual Meeting indicate.GSM, which includes vulvovaginal dryness, genital pain from intercourse, and genitourinary symptoms such as incontinence, can be treated with local vaginal estrogen, vaginal dehydroepiandrosterone, and oral ospemifene.Researchers, led by Isabella K.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
